Top

Published in:

Open Access 01-12-2024 | Breast Cancer | Research

SLC35A2 expression is associated with HER2 expression in breast cancer

Authors: Yiran Wang, Xiaobo Peng, Meihong Wu, Bin Wang, Tianran Chen, Xianbao Zhan

Published in: Discover Oncology | Issue 1/2024

Abstract

The role of SLC35A2 in breast cancer remains poorly understood, with limited available information on its significance. This study aimed to investigate the expression of SLC35A2 and clinicopathological variables in breast cancer patients. Immunohistochemical analysis of SLC35A2 protein was conductedon 40 adjacent non-neoplastic tissues and 320 breast cancer tissues. The study also assesed the association between SLC35A2 expression and breast cancer clinicopathological features of breast cancer, as well as its impact on overall survival. In comparison to adjacent non-neoplastic tissues, a significantly higher expression of SLC35A2 was observed in breast cancer tissues (P = 0.020), and this expression was found to be independently correlated with HER2 positivity (P = 0.001). Survival analysis indicated that patients with low SLC35A2 expression had a more favorable prognosis in HER2-positive subtype breast cancer (P = 0.017). These results suggest that SLC35A2 is overexpressed in breast cancer tissues compared to adjacent non-neoplastic tissues and may serve as a potential prognostic marker for HER2-positive subtype breast cancer. Furthermore, breast cancer patients with the HER2 positive subtype who exhibited decreased levels of SLC35A2 expression demonstrated improved long-term prognostic outcomes.

Heer E, Harper A, Escandor N, Sung H, McCormack V, Fidler-Benaoudia M. Global burden and trends in premenopausal and postmenopausal breast cancer: a population-based study. Lancet Glob Health. 2020;8(8):e1027–37. https://doi.org/10.1016/s2214-109x(20)30215-1.CrossRefPubMed

Siegel R, Miller K, Fuchs H, Jemal A. Cancer statistics, 2022. CA Cancer J Clin. 2022;72(1):7–33. https://doi.org/10.3322/caac.21708.CrossRefPubMed

Zheng R, Zhang S, Zeng H, Wang S, Sun K, Chen R, et al. Cancer incidence and mortality in China, 2016. J Natl Cancer Center. 2022.

Hao G, Ding Y, Wen H, Li X, Zhang W, Su H, et al. Attenuation of deregulated miR-369-3p expression sensitizes non-small cell lung cancer cells to cisplatin via modulation of the nucleotide sugar transporter SLC35F5. Biochem Biophys Res Commun. 2017;488(3):501–8. https://doi.org/10.1016/j.bbrc.2017.05.075.CrossRefPubMed

Wiktor M, Wiertelak W, Maszczak-Seneczko D, Balwierz P, Szulc B, Olczak M. Identification of novel potential interaction partners of UDP-galactose (SLC35A2), UDP-N-acetylglucosamine (SLC35A3) and an orphan (SLC35A4) nucleotide sugar transporters. J Proteomics. 2021;249: 104321. https://doi.org/10.1016/j.jprot.2021.104321.CrossRefPubMed

Li D, Mukhopadhyay S. A three-pocket model for substrate coordination and selectivity by the nucleotide sugar transporters SLC35A1 and SLC35A2. J Biol Chem. 2021;297(3): 101069. https://doi.org/10.1016/j.jbc.2021.101069.CrossRefPubMedPubMedCentral

Abuduxikuer K, Wang J. Four new cases of SLC35A2-CDG with novel mutations and clinical features. Front Genet. 2021;12: 658786. https://doi.org/10.3389/fgene.2021.658786.CrossRefPubMedPubMedCentral

Nguyen Y, To N, Truong V, Kim H, Ediriweera M, Lim Y, et al. Impairment of glucose metabolism and suppression of stemness in MCF-7/SC human breast cancer stem cells by nootkatone. Pharmaceutics. 2022. https://doi.org/10.3390/pharmaceutics14050906.CrossRefPubMedPubMedCentral

Ta H, Minh Xuan D, Tang W, Anuraga G, Ni Y, Pan S, et al. Novel insights into the prognosis and immunological value of the SLC35A (Solute Carrier 35A) family genes in human breast cancer. Biomedicines. 2021. https://doi.org/10.3390/biomedicines9121804.CrossRefPubMedPubMedCentral

10.

Wang J, Wang Y, Long F, Yan F, Wang N, Wang YJP. The expression and clinical significance of GADD45A in breast cancer patients. PeerJ. 2018;6:e5344. https://doi.org/10.7717/peerj.5344.CrossRefPubMedPubMedCentral

11.

Wang Y, Wang J, Long F, Wang N, Zhang B, Han H, et al. Correlation of FANCM expression with clinical factors in luminal B breast cancer. Breast Cancer. 2018;25(4):431–7. https://doi.org/10.1007/s12282-018-0841-0.CrossRefPubMed

12.

Hadley B, Litfin T, Day C, Haselhorst T, Zhou Y, Tiralongo J. Nucleotide sugar transporter SLC35 family structure and function. Comput Struct Biotechnol J. 2019;17:1123–34. https://doi.org/10.1016/j.csbj.2019.08.002.CrossRefPubMedPubMedCentral

13.

Song W, Isaji T, Nakano M, Liang C, Fukuda T, Gu J. O-GlcNAcylation regulates β1,4-GlcNAc-branched N-glycan biosynthesis via the OGT/SLC35A3/GnT-IV axis. FASEB J. 2022;36(2): e22149. https://doi.org/10.1096/fj.202101520R.CrossRefPubMed

14.

Miller K, Koboldt D, Schieffer K, Bedrosian T, Crist E, Sheline A, et al. SLC35A2Somatic mosaicism correlates with clinical findings in epilepsy brain tissue. Neurol Genet. 2020;6(4): e460. https://doi.org/10.1212/nxg.0000000000000460.CrossRefPubMedPubMedCentral

15.

Quelhas D, Correia J, Jaeken J, Azevedo L, Lopes-Marques M, Bandeira A, et al. SLC35A2-CDG: novel variant and review. Mol Genet Metab Rep. 2021;26: 100717. https://doi.org/10.1016/j.ymgmr.2021.100717.CrossRefPubMedPubMedCentral

16.

Witters P, Tahata S, Barone R, Õunap K, Salvarinova R, Grønborg S, et al. Clinical and biochemical improvement with galactose supplementation in SLC35A2-CDG. Genet Med. 2020;22(6):1102–7. https://doi.org/10.1038/s41436-020-0767-8.CrossRefPubMedPubMedCentral

17.

Bonduelle T, Hartlieb T, Baldassari S, Sim N, Kim S, Kang H, et al. Frequent SLC35A2 brain mosaicism in mild malformation of cortical development with oligodendroglial hyperplasia in epilepsy (MOGHE). Acta Neuropathol Commun. 2021;9(1):3. https://doi.org/10.1186/s40478-020-01085-3.CrossRefPubMedPubMedCentral

18.

Sun X, Yuan Z, Zhang L, Ren M, Yang J, Xu Y, et al. Comprehensive analysis of SLC35A2 in pan-cancer and validation of its role in breast cancer. J Inflamm Res. 2023;16:3381–98. https://doi.org/10.2147/jir.S419994.CrossRefPubMedPubMedCentral

19.

Yang X, Tao Y, Xu Y, Cai W, Shao Q. SLC35A2 expression drives breast cancer progression via ERK pathway activation. FEBS J. 2023. https://doi.org/10.1111/febs.17044.CrossRefPubMed

20.

Zhang M, Wang H, Peng R, Xu F, Wang F, Zhao Q. Metabolism-associated molecular classification of colorectal cancer. Front Oncol. 2020;10: 602498. https://doi.org/10.3389/fonc.2020.602498.CrossRefPubMedPubMedCentral

21.

Shin E, Koo J. Glucose metabolism and glucose transporters in breast cancer. Front Cell Dev Biol. 2021;9: 728759. https://doi.org/10.3389/fcell.2021.728759.CrossRefPubMedPubMedCentral

22.

Chandrasekaran A, Kaushal K, Park C, Kim K, Ramakrishna S. USP32 confers cancer cell resistance to YM155 via promoting ER-associated degradation of solute carrier protein SLC35F2. Theranostics. 2021;11(20):9752–71. https://doi.org/10.7150/thno.63806.CrossRefPubMedPubMedCentral

23.

Olsson L, Lindmark G, Israelsson A, Korkocic D, Hammarström S, Hammarström M. CEACAM5, KLK6, SLC35D3, POSTN, and MUC2 mRNA analysis improves detection and allows characterization of tumor cells in lymph nodes of patients who have colon cancer. Dis Colon Rectum. 2021;64(11):1354–63. https://doi.org/10.1097/dcr.0000000000002151.CrossRefPubMedPubMedCentral

24.

Pellizzari G, Martinez O, Crescioli S, Page R, Di Meo A, Mele S, et al. Immunotherapy using IgE or CAR T cells for cancers expressing the tumor antigen SLC3A2. J Immunother Cancer. 2021. https://doi.org/10.1136/jitc-2020-002140.CrossRefPubMedPubMedCentral

25.

Xu S, Chen X, Fang J, Chu H, Fang S, Zeng L, et al. Comprehensive analysis of 33 human cancers reveals clinical implications and immunotherapeutic value of the solute carrier family 35 member A2. Front Immunol. 2023;14:1155182. https://doi.org/10.3389/fimmu.2023.1155182.CrossRefPubMedPubMedCentral

26.

Bian Y, Li W, Kremer D, Sajjakulnukit P, Li S, Crespo J, et al. Cancer SLC43A2 alters T cell methionine metabolism and histone methylation. Nature. 2020;585(7824):277–82. https://doi.org/10.1038/s41586-020-2682-1.CrossRefPubMedPubMedCentral

27.

Lu W, Toss M, Dawood M, Rakha E, Rajpoot N, Minhas F. SlideGraph: whole slide image level graphs to predict HER2 status in breast cancer. Med Image Anal. 2022;80: 102486. https://doi.org/10.1016/j.media.2022.102486.CrossRefPubMed

28.

Nader-Marta G, Martins-Branco D, de Azambuja E. How we treat patients with metastatic HER2-positive breast cancer. ESMO Open. 2022;7(1): 100343. https://doi.org/10.1016/j.esmoop.2021.100343.CrossRefPubMedPubMedCentral

29.

Blangé D, Stroes C, Derks S, Bijlsma M, van Laarhoven H. Resistance mechanisms to HER2-targeted therapy in gastroesophageal adenocarcinoma: a systematic review. Cancer Treat Rev. 2022;108: 102418. https://doi.org/10.1016/j.ctrv.2022.102418.CrossRefPubMed

30.

Mukohara T. Mechanisms of resistance to anti-human epidermal growth factor receptor 2 agents in breast cancer. Cancer Sci. 2011;102(1):1–8. https://doi.org/10.1111/j.1349-7006.2010.01711.x.CrossRefPubMed

Title: SLC35A2 expression is associated with HER2 expression in breast cancer
Authors: Yiran Wang
Xiaobo Peng
Meihong Wu
Bin Wang
Tianran Chen
Xianbao Zhan
Publication date: 01-12-2024
Publisher: Springer US
Keywords: Breast Cancer
Breast Cancer
Published in: Discover Oncology / Issue 1/2024
Print ISSN: 1868-8497
Electronic ISSN: 2730-6011
DOI: https://doi.org/10.1007/s12672-024-00978-2

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2024

A new prognostic model based on gamma-delta T cells for predicting the risk and aiding in the treatment of clear cell renal cell carcinoma

miR-4429 inhibits ccRCC proliferation, migration, and invasion by directly targeting CD274

The role of tumor parenchyma and brain cortex signal intensity ratio in differentiating solitary fibrous tumors and meningiomas

Should we consider Systemic Inflammatory Response Index (SIRI) as a new diagnostic marker for rectal cancer?

A rare case report: multiple intrahepatic masses in a pediatric patient with citrin deficiency

Transarterial chemoembolization with/without immune checkpoint inhibitors plus tyrosine kinase inhibitors for unresectable hepatocellular carcinoma: a single center, propensity score matching real-world study

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials